Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 68 results:
Συντάκτης [ Τίτλος] Τύπος Έτος Φίλτρα: Συντάκτης is Sarafidis, Pantelis [Clear All Filters]
β-Thalassemia and renal complications. A narrative review of pathophysiologic mechanisms.
Integrative Molecular Medicine. 5(4),
(2018). Treatment-resistant hypertension in the hemodialysis population: a 44-h ambulatory blood pressure monitoring-based study..
J Hypertens. 38(9), 1849-1856.
(2020).
(2020). The systemic nature of CKD..
Nat Rev Nephrol. 13(6), 344-358.
(2017). Suprarenal graft fixation in endovascular abdominal aortic aneurysm repair is associated with a decrease in renal function..
J Vasc Surg. 56(3), 594-600.
(2012). A study of the association of higher parathormone levels with health-related quality of life in hemodialysis patients..
Clin Nephrol. 77(3), 196-203.
(2012). Soluble Klotho is associated with mortality and cardiovascular events in hemodialysis..
BMC Nephrol. 20(1), 217.
(2019). Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections..
Ann Intern Med. 171(12), 943-944.
(2019). Should renal color Doppler ultrasonography be a routine test in newly diagnosed hypertensive patient?.
J Hypertens. 36(1), 16-22.
(2018). SGLT-2 Inhibitors to Treat Hyponatremia Associated with SIADH: A Novel Indication?.
Am J Nephrol. 51(7), 553-555.
(2020). SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia..
Clin Kidney J. 13(5), 728-733.
(2020).
(2020). SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA..
Nephrol Dial Transplant. 34(2), 208-230.
(2019). SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA..
Nephrol Dial Transplant. 35(10), 1825.
(2020). Severe euglycemic diabetic ketoacidosis of multifactorial etiology in a type 2 diabetic patient treated with empagliflozin: case report and literature review..
BMC Nephrol. 21(1), 276.
(2020). Serum Creatinine and Chronic Kidney Disease-Epidemiology Estimated Glomerular Filtration Rate: Independent Predictors of Renal Replacement Therapy following Cardiac Surgery..
Am J Nephrol. 48(2), 108-117.
(2018). Scleroderma renal crisis accompanied by new-onset pulmonary arterial hypertension: an acute systemic endothelial injury? Case report and literature..
Inflamm Allergy Drug Targets. 9(4), 313-8.
(2010). Review of blood pressure control rates and outcomes..
J Am Soc Hypertens. 8(2), 127-41.
(2014). Renal Artery Stenosis in Patients with Resistant Hypertension: Stent It or Not?.
Curr Hypertens Rep. 19(1), 5.
(2017). The presence of diabetes mellitus further impairs structural and functional capillary density in patients with chronic kidney disease..
Microcirculation. e12665.
(2020). Pharmacotherapy of hypertension in patients with pre-dialysis chronic kidney disease..
Expert Opin Pharmacother. 21(10), 1201-1217.
(2020). The optimal blood pressure target in diabetes mellitus: a quest coming to an end?.
J Hum Hypertens. 32(10), 641-650.
(2018). A novel technique for repositioning, under local anesthetic, malfunctioning and migrated peritoneal dialysis catheters..
Perit Dial Int. 33(6), 700-4.
(2013). Nebivolol reduces short-term blood pressure variability more potently than irbesartan in patients with intradialytic hypertension..
Hypertens Res. 42(7), 1001-1010.
(2019).
(2020).